Entheseal power Doppler ultrasonography: a comparison of psoriatic arthritis and fibromyalgia

VOLUME 39: SUPPLEMENT 89

JULY 2012

Proceedings of the Second Update on Psoriatic Disease University Federico II Congress Center Naples, Italy July 6–7, 2011 Foreword: Second Update on Psoriatic Disease J.M.H. Moll . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 New Insights into the Concept of Psoriatic Disease R. Scarpa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4 Pathogenetic Overview of Psoriatic Disease M. Haroon, O. FitzGerald . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 The Synovio-entheseal Complex and Its Role in Tendon and Capsular Associated Inflammation D. McGonagle, S.Z. Aydin, A.L. Tan. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Th17 and IL-23 in the Pathogenesis of PsA and SpA A. Cauli, A. Mathieu . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Remission in PsA A. Caperon, P.S. Helliwell . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19 New Insights in Occult PsA C. Palazzi, S. D’Angelo, E. Lubrano, I. Olivieri . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22 Metabolic Syndrome in Patients with Psoriatic Disease J.M. Gelfand, H. Yeung . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24 Entheseal Power Doppler Ultrasonography: A Comparison of PsA and Fibromyalgia A. Marchesoni, O. De Lucia, L. Rotunno, G. De Marco, M. Manara . . . . . . . . . . . . . . . . . 29 Mortality and Causes of Death in PsA R. Arumugam, N.J. McHugh . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32 Osteoporosis and PsA A. Del Puente, A. Esposito, A. Parisi, et al . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36 PsA: Need for Ultrasound in Everyday Clinical Practice W. Grassi, M. Gutierrez . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39 Dynamic Contrast-enhanced MRI of Articular and Extraarticular Synovial Structures of the Hands in Patients with PsA   M.A. Cimmino, F. Barbieri, M. Boesen, et al . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44 New Developments in MRI of the Nail Unit E. Soscia, C. Sirignano, O. Catalano, et al . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 The Radiological Assessment of Axial Involvement in PsA   E. Lubrano, A. Marchesoni, I. Olivieri, et al . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54 Biomarker Development in PsA C. Ritchlin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57 Contents continued on back cover . . .

PRINTED IN CANADA – ISSN 0315-162X

Synovial Biomarkers in PsA U. Fiocco, F. Oliviero, P. Sfriso, et al . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61 Soluble Biomarkers May Differentiate Psoriasis from PsA   V. Chandran . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65 The Actual Role of Therapy with Traditional DMARD in PsA E.R. Soriano . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 67 Infliximab in PsA F. Cantini, L. Niccoli, C. Nannini, O. Kaloudi, E. Cassara . . . . . . . . . . . . . . . . . . . . . . . . . 71 Etanercept in PsA A. Spadaro, E. Lubrano, N. Ferrara, R. Scarpa . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74 Adalimumab in PsA C. Salvarani, N. Pipitone, M. Catanoso, et al . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77 Screening and Monitoring of Latent Tubercular Infection in Patients Taking TNF-a Blockers for PsA A. Sanduzzi, M. Bocchino, M. Atteno, et al . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82 Ustekinumab for Psoriasis and PsA A.B. Gottlieb, A.M. Goldminz . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86 Treatment of PsA with TNF Inhibitors: Longer-term Outcomes Including Enthesitis and Dactylitis with Golimumab Treatment in the Longterm Extension of a Randomized, Placebo-controlled Study (GO-REVEAL) A. Kavanaugh, P. Mease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 90 Should We Consider TNF as the Only Target in Spondyloarthritides? G. Ferraccioli, E. Gremese. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94 IL-6 Blockade: Tocilizumab in PsA F. Atzeni, D. Ventura, A. Batticciotto, L. Boccassini, P. Sarzi-Puttini . . . . . . . . . . . . . . . . . 97 The Inhibitor of Costimulation of T Cells: Abatacept F. Iannone, G. Lapadula . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100 Pharmacoeconomic Issues in PsA I. Olivieri, S. D’Angelo, C. Palazzi, A. Padula, E. Lubrano, L.G. Mantovani . . . . . . . . . . 103 Future Trends in Research in PsA D.D. Gladman. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106